The authors are likely to identify additional trials besides the 2 requested that assess the efficacy of SGLT-2 inhibitors and GLP-1 agonists versus placebo in patient with type 2 diabetes mellitus on cardiovascular outcomes. Will all the data be uploaded to the platform? Or is the purpose to use these data from the 2 trials, conduct the appropriate analyses, and then merge the summary data with already calculated estimates from previously acquired trials? I believe it’s the latter, which should just be explained a bit more clearly.
Approve